Lumos Pharma, Inc. (LUMO) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Austin, TX, United States. The current CEO is Richard J. Hawkins.
LUMO has IPO date of 2011-11-11, 30 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $37.54M.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
